Caredx Inc (NASDAQ:CDNA) price on Friday, June 13, fall -1.27% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $18.59.
A look at the stock’s price movement, the close in the last trading session was $18.83. The PE ratio in trailing twelve months stood at 16.13. Turning to its 52-week performance, $34.84 and $13.18 were the 52-week high and 52-week low respectively. Overall, CDNA moved 16.04% over the past month.
Caredx Inc’s market cap currently stands at around $1.04 billion, with investors looking forward to this quarter’s earnings report slated for in July.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend CDNA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CDNA’s current price about 2.71% and 6.37% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 53.90, while 7-day volatility ratio is 3.46% and 4.07% in the 30-day chart. Further, Caredx Inc (CDNA) has a beta value of 2.19, and an average true range (ATR) of 0.94. Analysts have given the company’s stock an average 52-week price target of $25, forecast between a low of $25 and high of $25. Looking at the price targets, the low is -34.48% off current price level while to achieve the yearly target high, price needs to move -34.48%. Nonetheless, investors will most likely welcome a -34.48% jump to $25 which is the analysts’ median price.
If we refocus on Caredx Inc (NASDAQ:CDNA), historical trading data shows that trading volumes averaged 1.02 million over the past 3 months. The company’s latest data on shares outstanding shows there are 55.46 million shares.
The 6.61% of Caredx Inc’s shares are in the hands of company insiders while institutional holders own 98.60% of the company’s shares. Current price change has pushed the stock -13.17% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CDNA stock continues to rise going into the next quarter.
